Loading candles…
Vimta Labs Ltd, incorporated in 1990 according to Screener, though Trendlyne cites its establishment in 1984, operates as a contract research and testing organization (CRTO). The company provides scientific services including analytical testing, preclinical and clinical research, and environmental consultancy. Serving industries such as pharmaceutical, biopharmaceutical, food, agrochemical, and electronics, Vimta Labs supports product safety and regulatory compliance. Its operations extend within India and globally. No information on founders, key management, subsidiaries, notable projects, or listings is provided.
This page is a live market overview for VIMTA LABS LIMITED (VIMTALABS) on the NSE. As a listed security, VIMTA LABS LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for VIMTALABS before placing trades on tick2trade.
As of the latest feed, VIMTALABS last traded at ₹651.25 on NSE, up ₹9.3 (1.45%) from the previous close of ₹641.95. Today's session range is ₹633.05 – ₹656.95, against a 52-week band of ₹376.05 – ₹902.65. Traded volume today stands at 1.61L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for VIMTALABS in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether VIMTALABS is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for VIMTA LABS LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in VIMTALABS. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated VIMTALABS option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 20 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 6 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 28 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 3 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 along with other items of agenda | 17 Jul 2025 |
| Bonus | To consider and approve allotment of Bonus Equity Shares. | 14 Jun 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025, dividend and bonus | 28 Apr 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.